Merit Medical Systems, Inc. (NASDAQ:MMSI) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $92.80.

MMSI has been the topic of several analyst reports. Barrington Research dropped their price target on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a research note on Monday, April 20th. Piper Sandler restated an “overweight” rating on shares of Merit Medical Systems in a research note on Friday. Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. Wall Street Zen cut Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 5th. Finally, Robert W. Baird set a $83.00 price objective on Merit Medical Systems in a report on Friday, May 1st.

Insider Transactions at Merit Medical Systems

In other news, insider Brian G. Lloyd bought 2,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was bought at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the transaction, the insider directly owned 2,000 shares in the company, valued at $125,240. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the transaction, the director owned 7,809 shares in the company, valued at approximately $488,921.49. This represents a 39.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL acquired a new stake in shares of Merit Medical Systems during the third quarter worth $2,913,050,000. SG Americas Securities LLC acquired a new position in Merit Medical Systems in the fourth quarter valued at about $1,537,000. Bessemer Group Inc. boosted its holdings in Merit Medical Systems by 54.2% during the fourth quarter. Bessemer Group Inc. now owns 313,981 shares of the medical instruments supplier’s stock worth $27,674,000 after buying an additional 110,392 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Merit Medical Systems by 7.6% during the third quarter. JPMorgan Chase & Co. now owns 917,122 shares of the medical instruments supplier’s stock worth $76,332,000 after buying an additional 64,920 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new position in shares of Merit Medical Systems during the 4th quarter worth about $12,239,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Price Performance

MMSI opened at $73.26 on Tuesday. The firm has a market capitalization of $4.37 billion, a P/E ratio of 31.71, a PEG ratio of 2.28 and a beta of 0.52. Merit Medical Systems has a 12-month low of $59.74 and a 12-month high of $94.75. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45. The stock has a fifty day moving average of $66.01 and a 200-day moving average of $72.92.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.10. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The business had revenue of $381.88 million during the quarter, compared to analyst estimates of $377.59 million. During the same period in the prior year, the firm earned $0.86 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Equities analysts forecast that Merit Medical Systems will post 3.62 EPS for the current fiscal year.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.